Targeted radiotherapy of the bone marrow using radiolabeled monoclonal antibodies is a therapeutic approach of considerable potential for the treatment of acute leukemia in addition to or as a substitute for total body irradiation. The data currently available, of about 300 patients, suggest that radioimmunotherapy (RIT) with b-emitters in acute leukemia is feasible and safe using a variety of antibodies (anti-CD33, anti-CD45, anti-CD66) and radionuclides ( 131 I, 90 Y, 188 Re). It appears to reduce the risk of relapse in high-risk acute myelogenous leukemia (AML) patients transplanted early in the course of their disease (o15% blasts) to 20-30%. Furthermore, it has shown the potential to safely intensify reduced-intensity conditioning regimens (nonrelapse mortality of 25% compared to relapse rate of 55% within 2 years). Significant improvements in the results of refractory patients will probably depend on the successful further development of RIT with a-emitters or the use of a cocktail of antibodies labeled with a-and b-emitters, in a first dose escalation study of 213 Bi-labeled anti-CD33 in refractory AML (partial) remission could be achieved in 5/18 patients. Randomized trials to evaluate the therapeutic efficacy of RIT in the context of stem cell transplantation have been initiated and the results are keenly anticipated.
apy; leukemia; radioisotopes; conditioning; stem cell transplantation
Background
Despite advances in therapy, only about 20-30% of patients with high-risk acute myelogenous leukemia (AML) and 30-40% of adults with high-risk acute lymphoblastic leukemia (ALL) become long-term survivors after hemopoietic stem cell transplantation (HSCT) with standard conditioning. 1, 2 The most common cause of treatment failure is relapse. In addition, the toxicity of chemotherapy and complications of HSCT contribute significantly to mortality rates. Escalation of total body irradiation (TBI) significantly reduces the risk of relapse in acute and chronic myeloid leukemia, but increases organ toxicity and transplantation-related mortality, resulting in unchanged patient survival. 3, 4 Therefore, intensifying conditioning by more selective irradiation of the bone marrow might reduce the risk of relapse while causing only limited toxicity to nontarget organs. Myeloablative radioimmunotherapy (RIT) is a promising approach for increasing the specific radiation dose to the bone marrow without increasing extramedullary toxicity. 5 In this paper, we review the literature and summarize unpublished work presented at a symposium held in Dresden in May 2004 under the auspices of the German Jose´Carreras Foundation.
Isotopes, antibodies, labeling and quality control
When selecting a radioisotope for clinical use, the characteristics of the isotope must be considered. The physical properties of several commonly used isotopes for the RIT of leukemia are summarized in Table 1 .
Crossfiring b-particles create a field effect, potentially irradiating antigen-negative tumor cells and making them useful in treating bulky disease and in selectively irradiating the entire bone marrow before HSCT. Most clinical studies have used 131 I, a long-lived b-particle emitter. The gemission from 131 I allows dosimetry studies to be performed easily, but treatment at high doses requires patient isolation. 6 90 Y is a pure b-emitter; its lack of g-emission allows outpatient administration of high doses but dosimetry is not trivial, whereas the accompanying g-emission of 188 Re is suitable for biodistribution and dosimetry studies with the same radionuclide. 7, 8 a-particles are helium nuclei emitted from the decay of radioisotopes. RIT with a-emitters, such as 213 Bi, 225 Ac and 211 At, should result in less nonspecific toxicity to normal bystander cells and in more efficient single-cell killing than b-emitting constructs.
Murine, chimeric and humanized monoclonal antibodies (Mabs) actually used are listed in Table 2 . [9] [10] [11] [12] [13] [14] [15] One advantage of the anti-CD66 antibody is its availability as a commercial kit for other purposes in nuclear medicine. The ideal labeling method for a particular Mab is influenced by the homogeneity of antigen expression and by the biological fate of the target antigen after the labeled Mab-antigen complex is formed. 16, 17 The first clinical trials involved Mabs labeled with 131 I for imaging and immunotherapy. The commonly used labeling procedures are seen in Table 3 . 10, 12, [18] [19] [20] [21] [22] The immunoreactivity of the labeled Mab remains the most important quality control measure and can be checked by FACS analysis or by reaction with granulocytes. 23 Although direct labeling is not ideal, it is effective and leads to good results in RIT. 24 
Dosimetry and radiation biology
After application of a trace dose of the radioimmunoconjugate, several planar whole-body scintigraphies are performed. 25 Absorbed doses are estimated using methods recommended by the Society of Nuclear Medicine's special committee on Medical Internal Radiation Dose (MIR-DOSE3 software). 26 Differences in dosimetry resulting from different biodistributions of the Mabs and different radioisotopes used are summarized in Table 4 . Dosimetry as currently practiced is based on conventional scintigraphy. The use of PET dosimetry should significantly improve the accuracy due to the higher sensitivity and the use of tomographic images. 27 The molecular radiobiology of b-irradiation has been poorly defined so far. g-and b-Irradiation both activated the ligand/receptor and mitochondrial pathways of apoptosis, but the kinetics and the influence of dose rate were different. 28 g-Irradiation resulted in a more rapid induction of apoptosis and b-irradiation was most effective in inducing apoptosis when used at low dose rates. Resistance to apoptosis appeared to be due to the induction of DNA repair.
Clinical studies
There are essentially three groups of trials that differ in their target antigens and the radionuclides used. The Seattle I-labeled anti-CD45 antibody (Table 5) The Seattle group has performed a series of studies using the 131 I-labeled anti-CD45 antibody. The initial phase I with 34 refractory AML/ALL demonstrated the feasibility and safety of the approach when used in combination with standard TBI/Ctx. The labeled antibody provided a mean red marrow dose of 24 Gy. The overall leukemia-free survival (LFS) was 29%. 21 Subsequently, two phase II studies were performed. The first study recruited 17 patients with advanced AML. They were treated with TBI 12 Gy/Ctx 120 mg/kg in addition to the radioconjugate that provided a marrow dose of 21-22 Gy. Both matched related (MRD) and matched unrelated donors (MUD) were permitted. LFS was 42%, with relapse (29%) and nonrelapse mortality (NRM, 29%) contributing equally to treatment failure. The outcome in the MRD group and the MUD group were identical. In the second trial, 46 patients with AML in CR1 with intermediate-risk or high-risk cytogenetic features were treated with the radioimmunoconjugate in combination with targeted Bu (16 mg/kg)/Ctx (120 mg/kg) using family donors. The mean red marrow dose achieved was 11 Gy. Overall LFS was 60%. LFS for the intermediate-risk patients was 68%, for high-risk patients 40%. The difference was due to the higher relapse rate in the high-risk group (33 vs 12%).
The Seattle group has also initiated a phase I trial of RIT in combination with their reduced -intensity conditioning protocol of TBI 2 Gy/fludarabine 30, 31 for patients with advanced AML over the age of 50 years. In all, 11 patients with a median age of 60 years have so far been recruited. The mean marrow dose delivered by the radiolabeled antibody has been 24 Gy. Donors have included both MRD and MUD. All 11 patients are currently alive, and eight are in remission.
Studies with radiolabeled anti-CD33 antibodies (Tables 6 and 7) The work of the group at Memorial Sloan-Kettering focused on the use of anti-CD33 Mabs initially with the murine antibody (M195), and subsequently with the humanized form of the antibody (HuM195). RIT has been utilized in the setting of both myeloablative conditioning prior to stem cell transplantation and nonmyeloablative treatment of refractory leukemias. Both M195 and HuM195 have been used as 131 I-labeled radioimmunoconjugates to intensify the conditioning regimen prior to HSCT in patients with relapsed/refractory AML and CML. The updated results of the initial phase I study of 31 patients show a 20% long-term survival rate for patients with AML; none of the CML patients survived long term. 10 More recently, 90 Y has been used as therapeutic nuclide, 213 Bi has been attached to HuM195 using the chelator CHX -A-DTPA. In two phase I studies, 213 Bi-labeled antiHuM195 was evaluated in 18 patients with refractory AML. 32 The conjugate localized to the marrow, spleen and liver, and the marrow to whole-body ratio was very much more favorable than for 131 I or 90 Y. All patients responded with a reduction of blasts in the marrow, but no CRs were observed. In the second study, the Ac is attached to HuM195 using the MeO -DOTA -NCS chelator. 225 Ac has a physical half-life of 10 days and decays with the release of four a-particles. This construct is very stable in vitro and very much more potent in killing tumor cell lines in vitro than 213 Bi. In xenograft mouse models, this construct also proved highly effective in killing human prostate cancer, ovarian cancer and lymphoma cell lines in vivo.
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Studies with labeled anti-CD66 antibodies (Table 8) A total of six studies using anti-CD66 antibody labeled with either 188 Re or 90 Y from five groups are available. The radioimmunoconjugate was used to intensify the conditioning regimen prior to HSCT in three studies and as part of a reduced-intensity conditioning regimen in three studies. The salient features of the phase I-II study of Bunjes et al are the inclusion of patients with high-risk AML/MDS in CR or PR, the use of T cell depletion either by CD34 þ selection or the use of Campath 1H in the bag as GvHD-prophylaxis 34 and the use of both MRD and alternative donors. The study recruited 55 patients. 13, 29 RIT provided a mean radiation dose to the marrow of 15.6 Gy, the kidney was the normal organ with the highest radiation exposure (7.2 Gy). Additional conditioning consisted of either a Bu/Ctx-based (n ¼ 29) or a TBI/Cybased (n ¼ 26) regimen. NRM was 25% at median followup. Radiation nephropathy was observed as a delayed complication in 11% of patients. After a median follow-up of 61 months, the LFS for the whole group of patients was 47%, with relapse (28%) and NRM (25%) contributing equally to treatment failure. Residual leukemia at the time of transplant determined outcome with an LFS of 59% for patients with a CR or good PR (o15% blasts) compared with an LFS of 8% for patients with 415% blasts.
In the Hannover group, no TBI was used in the conditioning and patients received unmanipulated grafts and conventional GvHD -prophylaxis. In this setting, the toxicity profile was different. Three patients developed VOD, which was fatal in two; however, no cases of radiation nephropathy were observed. After a median follow-up of 25 months, the LFS was 60%, with NRM and relapse contributing equally to treatment failure. There was no significant difference in outcome between patients transplanted in remission and those with active disease at transplant, suggesting that conventional GvHD -prophylaxis is more appropriate than T cell depletion in this group of patients.
In 17 pediatric patients with very high-risk acute leukemias (eight AML, eight ALL, one biphenotypic), the anti-CD66 antibody labeled with either 188 Re (n ¼ 14) or 90 Y (n ¼ 3) was used to intensify the conditioning regimen. The labeled antibody provided a mean marrow dose of 15.1 Gy and the kidney was the normal organ with the highest radiation exposure (mean 6.2 Gy). The standard conditioning given after RIT was predominantly TBI based. Eleven patients received grafts from alternative donors (including six haploidentical donors). T cell depletion was used for haploidentical HSCT and the other patients received conventional GvHD -prophylaxis. NRM (53%) was the major cause of treatment failure, with two patients developing fatal thrombotic-thrombocytopenic purpura (TTP). The relapse rate was 23%. After a median follow-up of 22 months LFS was 24%. All long-term survivors were in remission prior to transplant. 2 )/ ATG and grafts T cell depleted by the Campath 1H in the bag approach. 35 The eight patients with MUD donors were treated with fludarabine 150 mg/m 2 and melphalan 140 mg/m 2 and GvHD -prophylaxis consisted of 100 mg of Campath 1H intravenously (i.v.) þ cyclosporine. 36 Organ toxicity was low in these patients (5% grade III toxicity), with no cases of radiation nephropathy. With a median follow-up of 23 months, overall survival at 1 year was 70%, and at 2 years 52%. 37 Relapse (55%) was the main cause of treatment failure; the NRM was 25%. In Hannover, a further 10 patients were treated with 188 Re-labeled anti-CD66 antibody as part of an RIC regimen consisting of fludarabine/busulfan (n ¼ 7) or fludarabine/melphalan (n ¼ 3). All patients were given conventional GvHDprophylaxis. Relapse was the major cause of treatment failure and correlated with the remission status at transplant. LFS was 30%.
In Dresden, very preliminary data are available on a study recruiting patients aged 55-70 years of age with AML or high-risk MDS. The conditioning regimen consists of RIT with 188 Re-labeled anti-CD66 antibody, fludarabine 150 mg/m 2 and busulfan 4 mg/kg. GvHD -prophylaxis consists of Campath 1 H 75 mg i.v. and cyclosporine. Five patients have so far been included in the study. NRM has been zero, but two patients have relapsed early.
Conclusions and future perspectives
The results in high-risk AML patients grafted in remission are highly encouraging and a randomized trial to evaluate the role of intensified conditioning with radioimmunoconjugates is about to begin in the USA. The use of radioimmunoconjugates in the context of RIC regimens is an attractive concept, but further phase I-II studies are needed to define the optimal RIC regimen. Progress in the treatment of patients with refractory disease will probably require combinations of antibodies and nuclides and may also benefit from the development of pre-targeting strategies, which have been successful in animal models. 38 Finally, the increased use of tomographic techniques such as PET-CT should result in a significant improvement in dosimetry.
